KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
CA2395713C
(en)
|
2000-01-10 |
2012-04-10 |
Torben Lauesgaard Nissen |
G-csf conjugates
|
CN100488562C
(zh)
|
2000-02-11 |
2009-05-20 |
拜耳医药保健有限公司 |
凝血因子VⅡ或VⅡa样分子
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
EP1525889A1
(en)
†
|
2000-05-15 |
2005-04-27 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivative
|
US6951939B2
(en)
|
2000-06-08 |
2005-10-04 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
WO2002004015A1
(en)
*
|
2000-07-12 |
2002-01-17 |
Gryphon Therapeutics, Inc. |
Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
AU2001278905B2
(en)
*
|
2000-09-08 |
2004-12-16 |
Gryphon Therapeutics, Inc. |
Synthetic erythropoiesis stimulating proteins
|
WO2002032957A1
(fr)
*
|
2000-10-16 |
2002-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Erythropoietine modifiee par peg
|
CA2431964C
(en)
|
2000-12-20 |
2013-09-10 |
F. Hoffmann-La Roche Ag |
Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
|
ATE361089T1
(de)
|
2001-02-02 |
2007-05-15 |
Ortho Mcneil Pharm Inc |
Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
|
EP2080771A3
(en)
|
2001-02-27 |
2010-01-06 |
Maxygen Aps |
New interferon beta-like molecules
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
BR0214557A
(pt)
|
2001-11-28 |
2006-06-06 |
Ortho Mcneil Pharm Inc |
regime de dosagem de eritropoietina para o tratamento de anemia
|
AU2003218045A1
(en)
|
2002-03-11 |
2003-09-29 |
Ortho Mcneil Pharmaceutical, Inc |
Methods for shp1 mediated neuroprotection
|
DK1517710T3
(da)
|
2002-06-21 |
2011-07-18 |
Novo Nordisk Healthcare Ag |
Pegylerede faktor VII-glycoformer
|
AU2003254023A1
(en)
*
|
2002-07-19 |
2004-02-09 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
US20040091961A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Evans Glen A. |
Enhanced variants of erythropoietin and methods of use
|
EA008866B1
(ru)
*
|
2002-12-26 |
2007-08-31 |
Маунтин Вью Фамэсьютикэлс, Инк. |
ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
TWI364295B
(en)
*
|
2002-12-26 |
2012-05-21 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
EP1616003A4
(en)
*
|
2002-12-30 |
2007-06-20 |
Gryphon Therapeutics Inc |
WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
NZ542094A
(en)
|
2003-03-14 |
2008-12-24 |
Neose Technologies Inc |
Branched polymer conjugates comprising a peptide and water-soluble polymer chains
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
US7691603B2
(en)
|
2003-04-09 |
2010-04-06 |
Novo Nordisk A/S |
Intracellular formation of peptide conjugates
|
KR101160611B1
(ko)
*
|
2003-05-12 |
2012-06-28 |
아피맥스, 인크. |
폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분
|
MXPA05012316A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos novedosos que se unen al receptor de la eritropoyetina.
|
BRPI0411160A
(pt)
|
2003-05-12 |
2006-07-11 |
Affymax Inc |
novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
|
EA010099B1
(ru)
*
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
|
US7074755B2
(en)
*
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
EP1641481A4
(en)
*
|
2003-05-30 |
2008-10-15 |
Centocor Inc |
TRAINING OF NEW ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
EP2263684A1
(en)
|
2003-10-10 |
2010-12-22 |
Novo Nordisk A/S |
IL-21 derivatives
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US7405198B2
(en)
|
2003-11-24 |
2008-07-29 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US7368169B2
(en)
*
|
2003-12-01 |
2008-05-06 |
Rutgers, The State University Of New Jersey |
Hydrazide compounds with angiogenic activity
|
ES2560657T3
(es)
|
2004-01-08 |
2016-02-22 |
Ratiopharm Gmbh |
Glicosilación con unión en O de péptidos G-CSF
|
ES2397241T3
(es)
|
2004-01-21 |
2013-03-05 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
US20070105770A1
(en)
*
|
2004-01-21 |
2007-05-10 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
JP4896745B2
(ja)
|
2004-02-02 |
2012-03-14 |
アンブレツクス・インコーポレイテツド |
修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
|
JP2008502788A
(ja)
*
|
2004-06-08 |
2008-01-31 |
アルザ コーポレイション |
4成分縮合反応による高分子コンジュゲートの調製
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
EA200700990A1
(ru)
*
|
2004-11-11 |
2008-04-28 |
Афимакс, Инк. |
Новые пептиды, которые связывают рецептор эритропоэтина
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
SI3130601T1
(sl)
*
|
2004-11-12 |
2020-11-30 |
Bayer Healthcare Llc |
Usmerjena modifikacija FVIII
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
CA2927595C
(en)
*
|
2004-12-22 |
2023-01-31 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
CN101087875B
(zh)
|
2004-12-22 |
2012-08-22 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
US8080391B2
(en)
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
US7714114B2
(en)
*
|
2005-02-16 |
2010-05-11 |
Nektar Therapeutics |
Conjugates of an EPO moiety and a polymer
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
CA2602654A1
(en)
|
2005-04-05 |
2006-10-12 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Method for shielding functional sites or epitopes on proteins
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
EP1888098A2
(en)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
SG165353A1
(en)
|
2005-06-03 |
2010-10-28 |
Ambrx Inc |
Improved human interferon molecules and their uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
WO2006135930A2
(en)
*
|
2005-06-13 |
2006-12-21 |
Nastech Pharmaceutical Company Inc. |
Transmucosal delivery of peptide derivatives
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
EP1928906A2
(en)
*
|
2005-08-30 |
2008-06-11 |
Novo Nordisk Health Care AG |
Liquid formulations of pegylated growth hormone
|
CN101291684A
(zh)
*
|
2005-10-21 |
2008-10-22 |
阿维季尼克斯股份有限公司 |
甘醇化和糖基化的禽类来源的治疗性蛋白
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
PT2339014E
(pt)
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Métodos e composições compreendendo aminoácidos não-naturais
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
MX2008014744A
(es)
*
|
2006-05-19 |
2009-02-10 |
Glycofi Inc |
Composiciones de eritrocpoyetina.
|
CA2653154A1
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Prolonged fix analogues and derivatives
|
EP2040757A2
(en)
|
2006-07-07 |
2009-04-01 |
Novo Nordisk Health Care AG |
New protein conjugates and methods for their preparation
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
SI2054074T1
(sl)
|
2006-08-04 |
2014-12-31 |
Prolong Pharmaceuticals Llc |
Modificiran eritropoetin
|
ES2465473T3
(es)
|
2006-09-08 |
2014-06-05 |
Ambrx, Inc. |
Transcripción de arnt supresor en células de vertebrado
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
US9133495B2
(en)
|
2006-09-08 |
2015-09-15 |
Ambrx, Inc. |
Hybrid suppressor tRNA for vertebrate cells
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
US8389482B2
(en)
|
2007-01-30 |
2013-03-05 |
New York University |
Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
|
EP2118127A4
(en)
*
|
2007-01-31 |
2010-12-01 |
Affymax Inc |
NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
|
ATE554785T1
(de)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
Modifizierte fgf-21 polypeptide und ihre verwendung
|
CN101796063B
(zh)
|
2007-04-03 |
2017-03-22 |
拉蒂奥法姆有限责任公司 |
使用糖聚乙二醇化g‑csf的治疗方法
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス,インコーポレイテッド |
修飾IFNβポリペプチドおよびこれらの使用
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
WO2009003188A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
DK2217265T3
(en)
|
2007-11-20 |
2017-07-03 |
Ambrx Inc |
Modified insulin polypeptides and their use
|
CN101456911A
(zh)
*
|
2007-12-12 |
2009-06-17 |
江苏豪森药业股份有限公司 |
促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
|
US20110124841A1
(en)
*
|
2007-12-13 |
2011-05-26 |
Monthony James F |
Polypeptides Modified by Protein Trans-Splicing Technology
|
EP2247743B1
(en)
|
2008-02-08 |
2016-04-06 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
JP5619630B2
(ja)
|
2008-02-27 |
2014-11-05 |
ノボ・ノルデイスク・エー/エス |
結合型第viii因子分子
|
BRPI0916515B8
(pt)
|
2008-07-23 |
2021-07-27 |
Ambrx Inc |
polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
|
EP2157432A1
(en)
*
|
2008-08-15 |
2010-02-24 |
Qiagen GmbH |
Method for analysing a complex sample by mass spectrometry
|
MX346001B
(es)
|
2008-09-26 |
2017-03-01 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
BRPI0919031A2
(pt)
|
2008-09-26 |
2014-09-23 |
Ambrx Inc |
Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
|
WO2010129248A1
(en)
|
2009-05-06 |
2010-11-11 |
Centocor Ortho Biotech Inc. |
Melanocortin receptor binding conjugates
|
EP3093029A1
(en)
*
|
2009-07-27 |
2016-11-16 |
Baxalta GmbH |
Blood coagulation protein conjugates
|
AU2010341518B2
(en)
|
2009-12-21 |
2014-01-09 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
CN102753573A
(zh)
|
2009-12-21 |
2012-10-24 |
Ambrx公司 |
经过修饰的牛促生长素多肽和其用途
|
EP3815708A1
(en)
|
2010-03-05 |
2021-05-05 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
EP4302783A3
(en)
|
2010-08-17 |
2024-03-13 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
CN102652836A
(zh)
*
|
2011-03-03 |
2012-09-05 |
华中科技大学同济医学院附属协和医院 |
靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
|
WO2013004607A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
CA2840221A1
(en)
|
2011-07-05 |
2013-01-10 |
Bioasis Technologies Inc. |
P97-antibody conjugates and methods of use
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CA2880162C
(en)
|
2012-07-31 |
2023-04-04 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
EP4074728A1
(en)
|
2012-08-31 |
2022-10-19 |
Sutro Biopharma, Inc. |
Modified peptides comprising an azido group
|
EP2920148B1
(en)
|
2012-11-16 |
2019-06-12 |
The Regents of the University of California |
Pictet-spengler ligation for protein chemical modification
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
CN102935236B
(zh)
*
|
2012-11-21 |
2015-08-26 |
武汉平华生物医药科技有限公司 |
一种具有p-糖蛋白抑制功能的抗肿瘤前药
|
CN110478481A
(zh)
|
2013-03-13 |
2019-11-22 |
比奥阿赛斯技术有限公司 |
p97片段及其应用
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
NZ717668A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
KR102320019B1
(ko)
|
2013-11-27 |
2021-11-01 |
레드우드 바이오사이언스 인코포레이티드 |
히드라지닐-피롤로 화합물 및 콘쥬게이트 제조 방법
|
PT3412302T
(pt)
|
2014-10-24 |
2021-06-09 |
Bristol Myers Squibb Co |
Polipéptidos de fgf-21 modificados e utilizações dos mesmos
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
CA3017527A1
(en)
|
2016-03-25 |
2017-09-28 |
Seattle Genetics, Inc. |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
JP2020512312A
(ja)
|
2017-03-24 |
2020-04-23 |
シアトル ジェネティックス, インコーポレイテッド |
グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
|
WO2019133399A1
(en)
|
2017-12-26 |
2019-07-04 |
Becton, Dickinson And Company |
Deep ultraviolet-excitable water-solvated polymeric dyes
|
EP3775052B1
(en)
|
2018-03-30 |
2024-06-05 |
Becton, Dickinson and Company |
Water-soluble polymeric dyes having pendant chromophores
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
CA3107332A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies Inc. |
Treatment of lymphatic metastases
|
AU2019337610A1
(en)
|
2018-09-11 |
2021-05-06 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
CN109400695B
(zh)
*
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
KR20220079606A
(ko)
|
2019-10-04 |
2022-06-13 |
씨젠 인크. |
캄프토테신 펩티드 접합체
|
EP4117732A1
(en)
|
2020-03-11 |
2023-01-18 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
CA3176248A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
CA3207893A1
(en)
|
2021-01-15 |
2022-07-21 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
MX2023009113A
(es)
|
2021-02-03 |
2023-08-10 |
Seagen Inc |
Conjugados y compuestos inmunoestimulantes.
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
WO2022251850A1
(en)
|
2021-05-28 |
2022-12-01 |
Seagen Inc. |
Anthracycline antibody conjugates
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2023083900A1
(en)
|
2021-11-09 |
2023-05-19 |
Tubulis Gmbh |
Conjugates comprising a phosphorus (v) and a drug moiety
|
US20230158154A1
(en)
|
2021-11-09 |
2023-05-25 |
Tubulis Gmbh |
Conjugates comprising a phosphorus (v) and a camptothecin moiety
|
WO2023178289A2
(en)
|
2022-03-17 |
2023-09-21 |
Seagen Inc. |
Camptothecin conjugates
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
WO2024083926A1
(en)
|
2022-10-18 |
2024-04-25 |
Tubulis Gmbh |
Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
|
WO2024083953A1
(en)
|
2022-10-18 |
2024-04-25 |
Tubulis Gmbh |
Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|